Mezagitamab
Pre-launchTAK-079 · Immune thrombocytopenia / IgA nephropathy
Anti-CD38 monoclonal antibody
2028 (expected)
Launch readiness
+2 pts MoM58
Regulatory
55
0
Trial momentum
66
+2
Evidence
61
+2
Access / HTA
38
+1
Digital momentum
49
+3
Competitive
63
+1
Milestone rail
2024
P2b ITP readout (durable response)
Feb 2026
P3 ITP initiated
2027
P3 enrollment complete (planned)
2028
Filings (planned)
Clinical trials
ClinicalTrials.gov · Sep 2026Active P3
1
Enrollment
41%
Completion in
24mo
Competing programs
7
Enrollment vs target41%
Publications
PubMed · Sep 2026Last 12m
22
Growth
18%
+18%
Top-journal share
14%
Blood · 3AJH · 4ASH abstracts · 8Other · 7
Regulatory
FDA / company disclosures · Sep 2026Orphan Drug (ITP)
2 of 4 tracked milestones complete
HTA / access
HTA agency trackers · Sep 2026NICE
planned
G-BA
planned
HAS
planned
CADTH
n/a
PBAC
n/a
Competitor landscape
Public pipelines · Sep 2026| Rival | Status | Launch in | Readiness | Δ efficacy |
|---|---|---|---|---|
Fostamatinib Rigel | Marketed | launched | 88 | -6 pts |
Rilzabrutinib Sanofi | Filed | 9 mo | 74 | +10 pts |
Niplate / Promacta Amgen / Novartis | Marketed SoC | launched | 100 | 0 pts |
x: efficacy Δ vs SoC · y: access readiness
Risk / opportunity radar
Composite model · Sep 2026CEO take
- Phase 3 underway in ITP; P2 data showed durable platelet responses
- Anti-CD38 space validated by competitors (daratumumab) but crowded
- Evidence base thin for launch scale — publication growth 2 pts only
- Digital footprint smallest in the prelaunch cohort (49/100)
- Decision point: indication sequencing ITP-first vs IgAN-first
Digital signal layer
Multi-source listening · Sep 2026Search interest index
Google Trends
33idx+4 pts
Congress abstracts 12m
ASCO / ASH / EHA / AAN / ACG
17abstracts+2 new
KOL share of voice
X / LinkedIn / podcasts
12%+1.8 pts
News & PR velocity
Press wires & trade media
9/mo+3 items
Patient community volume
Reddit / Inspire / patient forums
4.1k posts+0.6 k
Community sentiment
NLP over community posts
66/100+1 pt
Payer / formulary chatter
Payer bulletins / guidelines
6idx+5 pts